ECCO2017: European Cancer Congress

login
My congress planner

Industry Sessions

Friday 27 January

MSD

Personalized Medicine With PD-1 Therapy

Time: 17:30 - 19:00; Location: Room Varmus

 

MSD is a global health care leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work to deliver innovative health solutions and are committed to increasing access to health care.

 

-----------------------------------------------------------------------------------------------------------------------------------------------

TESARO Bio GmbH

A new PARP inhibitor coming to clinical practice?

Time: 17:30 - 19:00; Location: Room Blackburn

Prof. Ray-Coquard, Dr Lorusso, Prof. Sehouli, and the co-chairs Dr Mirza and Dr Ottevanger, are delighted to invite you to this TESARO-sponsored satellite symposium discussing the evolving treatment landscape for ovarian cancer and the impact of PARP inhibitors. Although patients with ovarian cancer initially respond to chemotherapy, this diminishes over time. PARP inhibitors offer a valuable new treatment choice for patients. This patient-focused symposium will review treatment strategies and recent key data for PARP inhibitors.

-----------------------------------------------------------------------------------------------------------------------------------------------

Saturday 28 January

Eisai Europe Ltd

Moving Beyond Monotherapy: The Future of RCC?

Time: 11:00 - 12:00; Location: Spotlight 1



The field of renal cell carcinoma is particularly dynamic, with several new agents approved by EMA during 2016 alone. With a plethora of ongoing clinical trials one of the main questions that still remains, is ‘Monotherapy or combination therapy for these patients?’  The Moving beyond Monotherapy: The Future of RCC?  Industry Spotlight session serves to focus on this topic and will be led by the prestigious faculty Professor Viktor Grünwald and Professor Manuela Schmidinger.

www.eisai.co.uk

----------------------------------------------------------------------------------------------------------------------------------------------- 

Bristol-Myers Squibb

From Emerging Evidence to Longer-Term Clinical Experience: Immuno-Oncology in Head & Neck Cancer, Lung Cancer, and Melanoma

Time: 13:15 - 14:45; Location: Room Folkman

 

 


-----------------------------------------------------------------------------------------------------------------------------------------------

Elsevier

Debating the optimal management in advanced and metastatic lung cancer: the right treatment for the right patient at the right time

Time: 13:15 - 14:45; Location: Room Weinberg
 


 

We warmly welcome you to this satellite symposium Debating the optimal management of advanced and metastatic lung cancer: the right treatment for the right patient at the right time.

We have assembled a distinguished faculty of experts, internationally recognized for their experience and knowledge in the field of non-small-cell lung cancer. The symposium will be highly interactive, with ample opportunity for you to provide input.

For more information, please go to: lungcancer.elsevierresource.com

-----------------------------------------------------------------------------------------------------------------------------------------------

Novartis

From Physician to Patient: Defining Treatment Benefit in Advanced RCC

Time: 13:15 - 14:45; Location: Room Blackburn

Please join us for an interactive symposium that will explore both physician and patient perspectives on the ongoing advances in the management of aRCC. Emerging data from clinical trials will be reviewed and insights from real-world experience will be discussed.

For additional details, please Click Here

We trust that you will find the symposium very informative, and we look forward to seeing you there.

-----------------------------------------------------------------------------------------------------------------------------------------------

Pfizer

New avenues in HR+ HER2- mBC: CDK4/6 inhibitors

Time: 13:15 - 14:45; Location: Room Curie



 

This satellite symposium, sponsored by Pfizer Oncology, will focus on the latest clinical experience with CDK4/6 inhibitors, as well as exploring how the standard of care for HR+/HER2– metastatic breast cancer (mBC) may evolve in 2017. Experts from the field will use patient cases, combined with the latest trial data, to share their clinical experience with palbociclib. Further details available here.

-----------------------------------------------------------------------------------------------------------------------------------------------

Lilly Oncology

Navigating perspectives on value of oncology innovation

Time: 15:00 - 16:30; Location: Spotlight 2

Cancer survival rates in Europe are higher than ever, with 83% of gains attributable to new treatments, including medicines. Yet there are wide variations between perspectives on what constitutes ‘value’ among the oncology community and decision-makers in Europe.  

If you’re attending ECCO 2017, join us on 28 January at 15.00 (Spotlight 2, Hall 1) for a Policy Debate on the topic of NAVIGATING PERSPECTIVES ON VALUE OF ONCOLOGY INNOVATION. Register here!

 

-----------------------------------------------------------------------------------------------------------------------------------------------

Novartis

The Art of Patient-Focused Care in Advanced Breast Cancer

Time: 18:45 - 20:15; Location: Room Varmus

This exciting Novartis-sponsored satellite symposium will highlight evolving treatment paradigms for patients with HR+, HER2– advanced breast cancer. Discussions will center on targeted combination therapy approaches, including efficacy, safety, and treatment sequencing. A mixture of case-based panel discussions and didactic lectures will review evidence from clinical trials and examine their relevance to clinical practice. Interactive question-and-answer sessions and engaging patient communication discussions will paint a complete picture of the changing landscape of patient care.

----------------------------------------------------------------------------------------------------------------------------------------------

Sunday 29 January

Eisai Europe Ltd

Halaven - Mechanisms of Action: Beyond Antimitotic Effects to Complex Changes in Tumor Biology

Time: 11:00 - 12:00; Location: Spotlight 1


The cytotoxic effects of Halaven (eribulin) via its tubulin-based antimitotic mechanisms are well known but there is also emerging evidence that eribulin exerts distinct effects on tumour biology that go beyond its anti-mitotic effects. Eribulin's effects on tumour biology have been observed and characterised both in preclinical models as well as in recent translational research in patients with advanced breast cancer. Please join Dr Bruce Littlefield to learn more about eribulin's dual mechanism of action.

www.eisai.co.uk

-----------------------------------------------------------------------------------------------------------------------------------------------

Bristol-Myers Squibb

Emerging Immuno-Oncology Research in Gastrointestinal Cancers

Time: 13:15 - 14:45; Location: Room Folkman

 

-----------------------------------------------------------------------------------------------------------------------------------------------

Ipsen

Raising the bar in the management of advanced Renal Cell Carcinoma (RCC)

Time: 13:15 - 14:45; Location: Room Weinberg


Join us for the Ipsen sponsored satellite symposium at ECCO this year, where John Haanen, Camillo Porta and Manuela Schmidinger will discuss how to raise the bar in the management of advanced renal cell carcinoma. In this era of expanding options for first- and second-line therapies, our faculty will put the new data into context, examine the implications for patients and explore the importance of personalised medicine. 

View the full agenda here.

-----------------------------------------------------------------------------------------------------------------------------------------------

Novartis Pharmaceuticals Corporation

Accelerating Research to Practice Through Partnership

Time: 13:30 - 14:30; Location: Spotlight 2


 

Accelerating Research to Practice Through Partnership: Interactive session led by Patient Organization Leaders and International Medical Experts and researchers exploring unique approaches to facilitate moving research into clinical practice. Hosted by Novartis.

-----------------------------------------------------------------------------------------------------------------------------------------------

Elsevier

Joining a conversation on the treatment evolution in advanced GI malignancies: yesterday, today, and tomorrow

Time: 18:45 - 20:15; Location: Room Zur Hausen

You are cordially invited to attend the Satellite Symposium Joining a conversation on the treatment evolution in advanced GI malignancies: yesterday, today, and tomorrow.

During this symposium, a distinguished faculty of experts will engage the audience in an interactive discussion on how to optimize the day-to-day management of patients with gastrointestinal malignancies.

For more information, please go to gastrointestinalcancer.elsevierresource.com

-----------------------------------------------------------------------------------------------------------------------------------------------

The Health Policy Partnership

Moving towards sustainable cancer care: Reducing inefficiencies, improving outcomes

Time: 18:45 - 20:15; Location: Room Blackburn

The All.Can initiative aims to help define better solutions for sustainable cancer care. It was established to create political and public engagement on the need to improve the efficiency of cancer care – by making sure resources are targeted towards what matters most to patients.

To learn more about All.Can, come along to the All.Can satellite symposium at ECCO 2017, Sunday 29th January at 18:45.

Official Sponsored Satellite Symposium @ European Cancer Congress #ECCOCongress

PRINT THIS PAGE Page last modified: